Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 150 of the 154 references it cites were found in a registry or an index; 45 of the 94 sources its claims cite were checked for support.

Neuron Loss in Alzheimer’s Disease: Translation in Transgenic Mouse Models

Open access
Wirths, Oliver, Zampar, Silvia · 2020 · International Journal of Molecular Sciences

Abstract

Transgenic mouse models represent an essential tool for the exploration of Alzheimer's disease (AD) pathological mechanisms and the development of novel treatments, which at present provide only symptomatic and transient effects. While a variety of mouse models successfully reflects the main neuropathological hallmarks of AD, such as extracellular amyloid-β (Aβ) deposits, intracellular accumulation of Tau protein, the development of micro- and astrogliosis, as well as behavioral deficits, substantial neuron loss, as a key feature of the disease, seems to be more difficult to achieve. In this review, we summarize information on classic and more recent transgenic mouse models for AD, focusing in particular on loss of pyramidal, inter-, and cholinergic neurons. Although the cause of neuron loss in AD is still a matter of scientific debate, it seems to be linked to intraneuronal Aβ accumulation in several transgenic mouse models, especially in pyramidal neurons.

Overview

CoChat Summary

TL;DR

This review argues that neuron loss in Alzheimer’s disease mouse models is most consistently seen when intraneuronal Aβ accumulation is present, especially in pyramidal neurons. It also surveys interneuron and cholinergic neuron loss in APP-based models and concludes that no single mouse model captures all aspects of AD.

Key findings

  • In APP/PS1KI mice, stereological quantifications showed a ~50% loss of CA1 neurons at 10 months, and ~30% loss already at 6 months, alongside intraneuronal Aβ accumulation.
  • In 5xFAD mice, significant loss of cortical layer 5 neurons was confirmed at 9 and 12 months; this was essentially prevented by BACE1 gene deletion.
  • In APP/Tau models, neuron loss was more pronounced: APP/Tau mice showed significantly reduced CA1 and entorhinal cortex neuron numbers, and 5xFAD/Tg30 mice showed ~25% loss of pyramidal neurons in the hippocampal CA1–CA4 area.
  • Other Aβ-only models also showed marked neuron loss: TBA2.1 mice had ~30% CA1 neuron loss at 3 months and ~50% less neurons at 5 months; TBA42 mice had an ~35% loss of CA1 pyramidal neurons in aged animals.

Methods

  • Narrative review of classic and newer transgenic AD mouse models, focused on neuron loss in pyramidal, interneuron, and cholinergic populations.
  • Synthesizes findings from multiple transgenic lines, including APP-overexpressing, Aβ-peptide-only, APP/Tau, and triple-transgenic models.
  • Main evidence comes from stereological neuron counts, immunohistochemistry for Aβ and neuronal markers, and reported behavioral/pathological phenotypes across published studies.

Limitations

  • The paper states that no single mouse model mimics all relevant aspects of AD.
  • It notes that the importance of intraneuronal Aβ for sporadic AD is still unclear, and that transient intraneuronal accumulations are hard to study in human post-mortem tissue.
  • Evident from the text: this is a review, so its conclusions depend on heterogeneous prior studies rather than a new unified experimental dataset.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/ijms21218144

Cites

150 of 150 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 (A) Schematic representation of mutant and wildtype (WT) human amyloid precursor protein (APP), highlighting the positions of mutations frequently used in APP transgenic mouse models of AD (modified from [7]). Cleavage by β-secretase (BACE1) initiates the generation of Aβ peptides with the liberation of the soluble sAPPβ fragment. The membrane-bound APP C-terminal fragment (β-CTF) is further cleaved by the γ-secretase complex to liberate Aβ and the APP intracellular domain (AICD). (B) Amino acid sequences and numbering of the most common Aβ variants present in transgenic AD mouse models.
Figure 1 (A) Schematic representation of mutant and wildtype (WT) human amyloid precursor protein (APP), highlighting the positions of mutations frequently used in APP transgenic mouse models of AD (modified from [7]). Cleavage by β-secretase (BACE1) initiates the generation of Aβ peptides with the liberation of the soluble sAPPβ fragment. The membrane-bound APP C-terminal fragment (β-CTF) is further cleaved by the γ-secretase complex to liberate Aβ and the APP intracellular domain (AICD). (B) Amino acid sequences and numbering of the most common Aβ variants present in transgenic AD mouse models.CC BY · PubMed Central
Figure 2 Intraneuronal Aβ accumulation in the CA1 region of 2- (A) and 6-month-old (B) APP/PS1KI mice, as well as in cortical layers ((C), 2-month-old). Six-month-old homozygous Tg4-42 mouse showing CA1 neuron loss together with intraneuronal Aβ accumulation (D,E) (higher magnification of area indicated in (D)).
Figure 2 Intraneuronal Aβ accumulation in the CA1 region of 2- (A) and 6-month-old (B) APP/PS1KI mice, as well as in cortical layers ((C), 2-month-old). Six-month-old homozygous Tg4-42 mouse showing CA1 neuron loss together with intraneuronal Aβ accumulation (D,E) (higher magnification of area indicated in (D)).CC BY · PubMed Central

Verification

Claims the paper makes

36 Valid · 1 Not valid · 22 Not checked · 7 Own results and interpretations

17 more claims · 4 with their cited sources checked

Create a free account to see all 66 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 43
  • Probably not a substantial claim. 3
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Citations

Cites

Show all 154 references

Cited by

See all 76

Metadata

Authors
Wirths, O., & Zampar, S.
Affiliations
Universitätsmedizin Göttingen (DE)
Corresponding author
Wirths, Oliver
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2020-10-30
Volume
21
Issue
21
Pages
8144
ISSN
1422-0067 (ISSN-L)
OpenAlex
W3096611573
Cited by
75
References
154
Citations by year
2026: 7 · 2025: 14 · 2024: 14 · 2023: 20 · 2022: 12 · 2021: 7 · 2020: 1
FWCI
1.27
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
Funders
  • Gerhard Hunsmann Stiftung (T0323-28817)
  • Alzheimer Forschung Initiative (16013)
  • Alzheimer Stiftung Göttingen (-)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
Alzheimer's disease, neuronal loss, transgenic mouse model, pyramidal neurons, cholinergic neurons, interneurons, intraneuronal amyloid-beta, amyloid plaques, neurodegeneration, tau pathology, astrocyte activation
MeSH terms
Alzheimer Disease, Animals, Humans, Mice, Transgenic, Neurons, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neuron Loss in Alzheimer’s Disease: Translation in Transgenic Mouse Models. https://app.cochat.ai/papers/10.3390/ijms21218144
The paper
Wirths, O., & Zampar, S. (2020). Neuron Loss in Alzheimer’s Disease: Translation in Transgenic Mouse Models. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms21218144

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.